COMMUNIQUÉS West-GlobeNewswire

Genfit: GENFIT Launches a Combination Therapy Clinical Program in NASH
23/05/2019
GENFIT Launches a Combination Therapy Clinical Program in NASH GENFIT has identified multiple therapeutic compounds synergistic with its lead asset, elafibranor (PPAR alpha/delta), for the treatment of NASH Combined [...]
Genfit : GENFIT lance un programme clinique de combinaisons thérapeutiques dans la NASH
23/05/2019
GENFIT lance un programme clinique de combinaisons thérapeutiques dans la NASH GENFIT a identifié plusieurs composés thérapeutiques présentant une activité synergique avec son composé phare, elafibranor (PPAR alpha/ [...]
GenMark Diagnostics to Participate in Upcoming Investor Conferences
23/05/2019
CARLSBAD, Calif., May 23, 2019 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to [...]
Sol-Gel to Present at Upcoming Healthcare Investor Conferences in June
23/05/2019
NESS ZIONA, Israel, May 23, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing [...]
Integra LifeSciences to participate in the Jefferies Healthcare Conference and the Raymond James Life Sciences and MedTech Conference in June 2019
23/05/2019
PLAINSBORO, N.J., May 23, 2019 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will present at the following healthcare conferences in June: On [...]
Acute Myocardial Infarction Patients Treated Early With Cell Therapy Delivered With BioCardia’s Helix Endocardial Delivery System Improved in Ejection Fraction and NYHA Class
23/05/2019
Late-Breaking Trial Session at EuroPCR Featured Positive Data on Helix System PARIS and SAN CARLOS, Calif., May 23, 2019 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [OTC: BCDA], a leader in the development of comprehensive [...]
Annual General Meeting of Active Biotech AB
23/05/2019
PRESS RELEASE The Annual General Meeting of Active Biotech was held on May 23, 2019. In accordance with the Board of Directors' proposal, it was resolved that no dividend would be paid. The members of the Board and the [...]
Merus annonce son Assemblée générale annuelles des actionnaires 2019
23/05/2019
UTRECHT, Pays-Bas, 23 mai 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS) (« Merus », « nous » ou la « Société »), société spécialisée en immuno-oncologie de stade clinique qui développe Biclonics®, un traitement [...]
Genkyotex Invites Shareholders to Annual General Meeting on June 13, 2019
23/05/2019
Documents related to AGM available on Genkyotex website or upon request Genkyotex advancing on strategy for further development of GKT831 in fibrotic liver diseases GKT831 Ph2 DKD trial progresses and Ph2 IPF trial [...]
Genkyotex invite ses actionnaires à l’Assemblée générale mixte du 13 juin 2019
23/05/2019
Modalités de mise à disposition des documents préparatoires Les informations et documents relatifs à l’Assemblée Générale sont disponibles sur simple demande ou peuvent être consultés sur le site internet de la Société [...]
Repeat: Inventiva announces that FDA lifts target class clinical hold which allows long-term clinical studies with lanifibranor in NASH
23/05/2019
Inventiva announces that FDA lifts target class clinical hold which allows long-term clinical studies with lanifibranor in NASH FDA decision based on the results of carcinogenicity studies Lanifibranor does not show any [...]
Repeat: Inventiva annonce que la FDA a levé la suspension clinique applicable aux agonistes PPAR ce qui permet de réaliser des études cliniques à long terme avec lanifibranor dans la NASH
23/05/2019
Inventiva annonce que la FDA a levé la suspension clinique applicable aux agonistes PPAR ce qui permet de réaliser des études cliniques à long terme avec lanifibranor dans la NASH La décision de la FDA est fondée sur [...]
Inventiva announces that FDA lifts target class clinical hold which allows long-term clinical studies with lanifibranor in NASH
23/05/2019
Inventiva announces that FDA lifts target class clinical hold which allows long-term clinical studies with lanifibranor in NASH FDA decision based on the results of carcinogenicity studies Lanifibranor does not show any [...]
Inventiva annonce que la FDA a levé la suspension clinique applicable aux agonistes PPAR ce qui permet de réaliser des études cliniques à long terme avec lanifibranor dans la NASH
23/05/2019
Inventiva annonce que la FDA a levé la suspension clinique applicable aux agonistes PPAR ce qui permet de réaliser des études cliniques à long terme avec lanifibranor dans la NASH La décision de la FDA est fondée sur [...]
Ahead of Memorial Day, the American Academy of Dermatology Reminds Americans to Use Protection
23/05/2019
Dermatologists urge the public to “practice safe sun” when outside this holiday weekend to reduce the risk of skin cancer ROSEMONT, Ill., May 23, 2019 (GLOBE NEWSWIRE) -- An estimated 9,500 people in the United States [...]
Nexstim Plc: Amendment of terms of warrants
23/05/2019
Company announcement, Helsinki, 23 May 2019 at 6.30 PM Nexstim Plc: Amendment of terms of warrants Nexstim Plc (NXTMH:HEX, NXTMS:STO) ( "Nexstim" or "Company" ), the targeted neuromodulation company developing and [...]
Max Domi, vedette des Canadiens de Montréal et porte-parole national de FRDJ, se joindra le 28 mai à des enfants de la région de Montréal qui vivent avec le diabète de type 1 pour avoir une discussion franche sur la maladie
23/05/2019
Cette conversation unique organisée aux Salles de Bal Le Windsor à Montréal donnera la chance à 13 jeunes de la région de poser des questions à Max sur ses expériences avec le Diabète de type 1 et sa participation [...]
Montreal Canadiens star and JDRF National Spokesperson Max Domi joins Montreal-area kids living with type 1 diabetes May 28 for a frank discussion on the disease
23/05/2019
Hosted from the Windsor Ballrooms in Montreal, the unique conversation features 13 young Canadians interviewing Domi on his experiences with T1D and upcoming participating in the Sun Life Walk to Cure Diabetes for JDRF [...]
Robust Clinical Data and Positive Customer Experience with T2Bacteria and T2Candida Panels Highlighted at Recent Medical Meetings
23/05/2019
Presentations at ECCMID and MAD-ID meetings demonstrate clinically actionable results and cost savings achieved with these panels Real-world experience reinforces multi-day time advantage demonstrated in the T2Bacteria [...]

Pages